Antithrombotic therapy in patients undergoing coronary angioplasty or coronary stent placement

Clinical and Applied Thrombosis/Hemostasis

Volumn 3, Issue 1 SUPPL., 1997, Pages

  Kugelmass, Aaron D ^a   Raskob, Gary E ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33847578217     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029697003001s05     Document Type: Article

References (77)

1. Popma JJ, Coller BS, Ohman EM,et al.Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1995; 108:486S.
2. Cook DJ, Guyatt GH, Laupacis A.,et al.Clinical recommendations using levels of evidence for antithrombotic agents. Chest 1995; 108: 227S.
3. Gruntzig AR, Senning A., Siegenthaler WE Nonoperative dilatation of coronary-artery stenosis. N Engl J Med 1979;301:61.
4. Topol EJ, Bonan R., Jewitt D.,et al.Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622.
5. Ferguson JJ, Dohmen P., Wilson JM,et al.Results of a national survey on anticoagulation for PTCA. J Invas Cardiol 1995;7:136.
6. Bull BS, Huse WM, Braver FS,et al.Heparin therapy during extracorporeal circulation II. The use of a dose response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975;69:685.
7. Young JA, Kisker CT, Doty DB Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978;26:231.
8. Avendano A., Ferguson JJ Comparison of HemoChron and Hemo-Tec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:907.
9. Dougherty KG, Gaos CM, Bush HS,et al.Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cath Cardiovasc Diag 1992;26:260.
10. Hattersley PG Activated coagulation time of whole blood. JAMA 1966;196:150.
11. Ferguson JJ, Dougherty KG, Gaos CM,et al.Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994; 23:1061.
12. McGarry TF, Gottlieb RS, Morganroth J.,et al.The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J 1992; 123:1445.
13. Kem MJ, Deligonul U., Presant S.,et al.Resolution of intraluminal thrombus with augmentation of heparin during percutaneous transluminal coronary angioplasty. Am J Cardiol 1986;58:852.
14. Grayburn PA, Willard JE, Brickner ME,et al.In vivo thrombus formation on a guidewire during intravascular ultrasound imaging: Evidence for inadequate heparinization. Cath Cardiovasc Diag 1991;23:141.
15. Gabliani G., Delingonul U., Kem MJ,et al.Acute coronary occlusion occurring after successful percutaneous transluminal coronary angioplasty: Temporal relationship to discontinuation of anticoagulation. Am Heart J 1988;116:696.
16. Narins CR, Hillegass WB, Nelson CL,et al.Activated clotting time predicts abrupt closure risk during angioplasty [Abstract]. J Am Coll Cardiol 1994;23:470A.
17. Ahmed WH, Meckel CR, Grines CL,et al.Relation between ischemic complications and activated clotting times during coronary angioplasty: Different profiles for heparin and hirulog [Abstract]. Circulation 1995;92:1-608.
18. Ogilby JD, Kopelman HA, Klein LW,et al.Adequate heparinization during PTCA: Assessment using activated clotting times. Cath Cardiovasc Diag 1989; 18:206.
19. Vaitkus PT, Herrmann HC, Laskey WK Management and immediate outcome of patients with intracoronary thrombus during percutaneous transluminal coronary angioplasty. Am Heart J 1992; 124: 1.
20. Ellis SG, Roubin GS, Wilentz J.,et al.Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989; 117:777.
21. Friedman HZ, Cragg DR, Glazier SM,et al.Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol 1994: 24: 1214.
22. Oweida SW, Roubin GS, Smith RB,et al.Postcatheterization vascular complications associated with percutaneous transluminal coronary angioplasty. J Vasc Surg 1990; 12:310.
23. Popma JJ, Satler LF, Pichard AD,et al,Vascular complications after balloon and new device angioplasty. Circulation 1993;88: 1569.
24. Moscucci M., Mansour KA, Kent KC,et al.Peripheral vascular complications of directional coronary atherectomy and stenting: Predictors, management, and outcome. Am J Cardiol 1994; 74:448.
25. Muller DWM, Shamir KJ, Ellis SG,et al, Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. Am J Cardiol 1992;69:63.
26. Schwartz L., Bourassa MG, Lesperance J.,et al.Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714.
27. White CW, Chaitman B., Lassar TA,et al.Antiplatelet agents are effective in reducing the immediate complications of PTCA: Results from the Ticlopidine Multicenter Trial [Abstract]. Circulation 1987;76:IV-400.
28. Bamathan ES, Schwartz JS, Taylor L.,et al.Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987;76:125.
29. Lembo NJ, Black Ajr, Roubin GS,et al.Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990;65:422.
30. Mufson L., Black A., Roubin G.,et al.A randomized trial of aspirin in PTCA: Effects of high vs low dose aspirin on major complications and restenosis [Abstract]. J Am Coll Cardiol 1988; 11:236A.
31. Myler RK, Shaw RE, Stertzer SH,et al.Lesion morphology and coronary angioplasty: Current experience and analysis. J Am Coll Cardiol 1992;19:1641.
32. Detre K., Holubkov R., Kelsey S.,et al.Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. N Engl J Med 1988;318:265.
33. Topol EJ Novel antithrombotic approaches to coronary artery disease. Am J Cardiol 1995;75:27B.
34. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956.
35. Topol EJ, Califf RM, Weisman HF,et al.Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994; 343;881.
36. Ferguson JJ IMPACT II results announced. Circulation 1995;92: 697.
37. Serruys PW, Herrman J-PR, Simon R.,et al.A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995; 333:757.
38. Bittl JA, Strony J., Brinker JA,et al.Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764.
39. Serruys PW, de Jaegere P., Kiemeneij F.,et al.A comparison of balloon-expandable-stent implantation with balloon,angiop4sty in patients with coronary artery disease. N Engl J Med 1994;331:489.
40. George BS, Voorhees WD, Roubin GS,et al.Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: Clinical and angiographic outcomes. J Am Coll Cardiol 1993;22:135.
41. Fischman DL, Leon MB, Baim DS,et al.A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496.
42. Serruys PW, Strauss BH, Beatt KJ,et al.Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med 1991;324:13.
43. Schatz RA, Baim DS, Leon M.,et al. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation 1991;83:148.
44. Nath FC, Muller DWM, Ellis SG,et al. Thrombosis of a flexible coil coronary stent. frequency, predictors and clinical outcome. J Am Coll Cardiol 1993; 21:622.
45. Colonibo A., Hall P., Nakamura S.,et al.Intracoronary stenting without anticoagulation accomplished with intravascular uhrasound guidance. Circulation 1995;91:1676.
46. Colombo A., Nakamura S., Hall P.,et al.A prospective study of Wiktor coronary stent imputation treated only with antiplatelet therapy [Abstract]. Circulation 1994;90:1-124.
47. Elias J., Monassier JP, Puel J.,et al.Medtronic Wiktor stent implantation without Coumadin: Hospital outcome [Abstract]. Circulation 1994;90:1-124.
48. Hall P., Colombo A., Nakamura S.,et al.A prospective study of Gianturco-Roubin coronary stent implantation without subsequent anticoagulation [Abstract]. Circulation 1994;90:1-124.
49. Aubry P., Royer T., Spaulding C.,et al. Coronary stenting without Coumadin: Phase 11 and 111. The Bail-out Group [Abstract]. Circulation 1994;90:1-124.
50. Blengino S. Maietto L. Hall P.,et al. Randomized trial of coronary stent imglantatican without anticoagutation: Aspirin vs ticlopidine [Abstract]. Circulation 1994.90:1-124.
51. Morice M-C. Bourdonnec C., Lefevre T.,et al.Coronary stenting without Coumadin. Phase III [Abstract]. Circulation 1994;90; 1-125.
52. Carvalho H., Fajadet J., Jordan C.,et al.A lower rate of complications after Gianturco-Roubin coronary stenting using a new antiplatelet and anticoagulant protocol [Abstract]. Circulation 1994;90:I-125.
53. Jordan C, Carvalho H, Fajadet J.,et al. Reduction of subacute thrombosis rate after coronary stenting using a new anticoagulant protocol [Abstract]. Circulation 1994;90:1-125.
54. Femandez-Aviles F., Alonso J., Duran JM,et al.Absence of bleeding and subacute occlusion after Palmaz-Schatz coronary stenting using a new antithrombotic regimen [Abstract]. J Am Coll Cardiol 1995; 25:196A.
55. Blengino S., Nakarnurra S., Hall P. A cost analysis of intravascular ultrasound guided coronary stenting without anticoagulation vs the traditional method of stenting with anticoagulation [Abstract]. J Am Coll Cardiol 1995;25:197A.
56. Blasini R., Mudra H., Schuhlen H.,et al.Intravascular ultmsound guided optimized emergency coronary Patmaz-Schatz stent placement without post procedural systemic anticoagulafion [Abstract]. J Am Coll Cardiol 1995:25:197A.
57. Van Belle E., McFadden EP, Bauters C.,et al. Combined antiplatelet therapy without anticoagulation: An effective alternative to prevent subacute thrombosis after coronary stenting? A 3 month follow-up [Abstract]. J Am Coll Cardiol 1995;25:197A.
58. Hall P., Colombo A., Itoh A.,et al.Gianturco-Roubin stent imptantation in small vessels without anticoagulation [Abstract]. Circulation 1995; 92:1-795.
59. Haase J., Reifart N., Baier T.,et al.Bail-out stenting (Palmaz-Schatz) without anticoagulation [Abstract]. Circulation 1995;92:1-795.
60. Wong SC, Hong MK, Chuang YC,et al.The anti-platelet treatment after intravascutaruttrasound guided optimal stent expansion (APLAUSE) trial [Abstract]. Circulation 1995;92:1-795.
61. Morice MC, Amor M., Benveniste E.et al. Coronary stenting without Coumadin Phase II, III, IV, V. Predictors of major complications [Abstract]. Circulation 1995;92:1-795.
62. Goods CM, Al-Shaibi K., Lyer S. Flexible coil coronary stenting without anticoagulation or intravascular ultrasound: A prospective observational study [Abstract]. Circulation 1995;92:1-795.
63. Belli G., Whitlow PL, Gross L.,et al.Intracoronary stenting without oral anticoagulation: The Cleveland Clinic Registry [Abstract]. Circulation 1995; 92:I-796.
64. Morice MC, Breton C., Bunouf P.,et al. Coronary stenting without anticoagulant, without intravascular ultrasound. Results of the French Registry [Abstract]. Circulation 1995;92:I-796.
65. Goods CM, Liu MW, Liyer SS, et al. A cost analysis of coronary stenting without anticoagulation versus stenting with anticoagulation using warfarin [Abstract]. Circulation 1995;92:I-796.
66. Taylor MA DiBlasi SL, Bender RM,et al.Adult respiratory distress syndrome complicating intravenous infusion of low-molecular weight dextran. Cath Cardiovse. Diagn 1994:32:249.
67. Popma JJ, Califf RM, Topol EJ Clinical trials of restenosis after coronary angioplasty. Circulation 1991;84:1426.
68. Brack MJ Ray S., Chauhan A.,et al.The subcutaneous heparin and angioplasty restenosis prevention (SHARP) trial. J Am Coll Cardiol 1995;26:947.
69. Faxon DP, Spiro TE, Minor S.,et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of enoxaparin restenosis (ERA) trial. Circulation 1994;90:908.
70. Thomton MA, Gruentzig AR, Holliman J.,et al.Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: A randomized study. Circulation 1984;69:721.
71. Purban Buller N, Fox K.,et al. Lack of effect of warfarin on the restenosis rate or on clinical outcome after balloon angioplasty. Br Heart J 1988;60:485.
72. Savage MP, Goldberg S., Bove AA,et al.Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Circulation 1995;92.3194.
73. Taylor RR Gibbons FA, Cope GD,et al.Effects of low-dose aspirin on restenosis after coronary angioplasty. Am J Cardiol 1991:68: 874.
74. Darius H., Sellig S., Belz GG,et al.Aspirin 500 mg/d is superior to 100 and 40 mg/d for prevention of restenosis following PTCA [Abstract. Circulation 1994;90:1-651.
75. Serruys PW, Putsch W., Heyndrickx GR,et al.Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. Circulation 1991;84: 1568.
76. Serruys PW, Klein W., Tijssen JPG,et al.Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Circulation 1993;88:1588.
77. Hyers T., Hull R., Weg J. Antithrombotic therapy for venous thromboembolic disease. Chest 1995;108:335S.